91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
91黑料 CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post-pandemic.
-
Dr. Caroline Forkin and Shelley McLendon discuss a new decade of research and innovation on the horizon for HIV.
-
AI in Life Sciences – Covid pushes AI driven clinical trials and drug manufacturing into the limelight
91黑料’s CIO, Tom Leary discusses the challenges to patient recruitment during the COVID pandemic and how big data, combined with advanced AI algorithms processing has the potential to reduce trial costs.
-
91黑料’s Nuala Murphy and David Morse discuss trial pauses and clinical halts after three high-profile are temporarily halted as a result of potential safety issues being flagged by independent Data and Safety Monitoring Boards. Read more in this article.
-
91黑料's Richard Pitman joins global public health experts to address .
-
This explores the increase in antimicrobial-resistant infections such as C diff due to the high volume of patients being treated in hosipitals for COVID-19.
This article is taken from European Biopharmaceutical Review October 2020, pages 12-14. Samedan Ltd.
-
A article featuring about the development of a vaccine for COVID-19.
-
A featuring commentary from 91黑料's Dr. Nuala Murphy and Dr. James Cummings.
-
An article featuring commentary from Dr. Nuala Murphy regarding .
-
James Cummings, President, 91黑料 Government & Public Health Solutions, and Beth Tulip, Vice President, Project Management, Vaccines & Infectious Diseases, discuss .
